BS006
/ Wuhan Binhui Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 21, 2026
Safety and preliminary efficacy of OH2 combined with BS006 sequential intratumoral injection in patients with advanced solid tumors: An open-label, dose-escalation phase Ib/II study.
(ASCO 2026)
- "Sequential intratumoral administration of OH2 and BS006 in heavily pre-treated patients is feasible and safe and results in reasonable DCR, with some patients achieving long-term clinical benefits. This study supports the clinical relevance of an HSV2-based platform combination of 2 oncolytic viruses encoding GM-CSF and T-cell redirected bispecific antibodies to warm up the cold TME. Further clinical research of the platform is warranted."
Clinical • Metastases • P1/2 data • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Colorectal Cancer • Leiomyosarcoma • Liver Cancer • Melanoma • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CSF2
February 03, 2026
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd.
New P1/2 trial • Biliary Tract Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Melanoma • Solid Tumor
November 20, 2025
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
(clinicaltrials.gov)
- P1 | N=29 | Suspended | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2026 ➔ Dec 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jun 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Trial suspension • Breast Cancer • Melanoma • Solid Tumor
December 26, 2023
oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection
(clinicaltrials.gov)
- P1 | N=29 | Recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2023 ➔ Dec 2023
Enrollment open • Metastases • Oncolytic virus • Trial initiation date • Breast Cancer • Melanoma • Oncology • Solid Tumor
July 10, 2023
oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection
(clinicaltrials.gov)
- P1 | N=29 | Not yet recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd.
Metastases • New P1 trial • Oncolytic virus • Breast Cancer • Melanoma • Oncology • Solid Tumor
May 26, 2022
CC-OV01: First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Zhongnan Hospital
New P1 trial • Cervical Cancer • Herpes Simplex • Oncology • Solid Tumor • Uterine Cancer
1 to 6
Of
6
Go to page
1